<DOC>
	<DOCNO>NCT02482168</DOCNO>
	<brief_summary>This study phase 1 open-label dose escalation study immuno-activating monoclonal antibody APX005M adult solid tumor . Study intend establish maximum tolerate dose overall safety tolerability APX005M .</brief_summary>
	<brief_title>Study CD40 Agonistic Monoclonal Antibody APX005M</brief_title>
	<detailed_description>APX005M-001 open-label study comprise dose-escalation portion approximately 8 dose level cohort , plus expansion cohort . Eligible subject solid tumor receive intravenous APX005M every 3 week disease progression , unacceptable toxicity death , whichever occur first . Study objectives include : - Evaluate safety APX005M - Determine maximum tolerate dose APX005M - Determine pharmacokinetic parameter APX005M : maximal drug concentration ( Cmax ) , area curve serum concentration time ( Area Under Curve/ AUC ) , half-life ( tÂ½ ) . - Preliminary assessment clinical response</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Histologically document diagnosis solid tumor No known effective therapy option available Measurable disease RECIST 1.1 ECOG performance status 0 1 Adequate bone marrow , liver kidney function No toxicity relate prior treatment related toxicity exception alopecia neuropathy Negative pregnancy test woman child bear potential Key Any history current hematologic malignancy Major surgery treatment investigational agent within 4 week Uncontrolled diabetes hypertension History arterial thromboembolic event History congestive heart failure , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention , myocardial infarction Active know clinically serious infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>immunotherapy</keyword>
	<keyword>CD40</keyword>
</DOC>